Overview

Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP). The names of the study drugs involved in this study are: - Pembrolizumab - Lenvatinib

Phase:

Phase 2

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborators:

Eisai Inc.
Merck Sharp & Dohme Corp.

Treatments:

Lenvatinib
Pembrolizumab